Sk Biopharmaceuticals Co Ltd Total Liabilities
Sk Biopharmaceuticals Co Ltd total liabilities. Based on the latest financial reports, Sk Biopharmaceuticals Co Ltd (326030) has total liabilities worth ₩388.37 Billion KRW (≈ $263.19 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Sk Biopharmaceuticals Co Ltd (326030) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Sk Biopharmaceuticals Co Ltd (2016–2025)
Total liabilities of Sk Biopharmaceuticals Co Ltd from 2016 to 2025. This chart illustrates how Sk Biopharmaceuticals Co Ltd's total liabilities have evolved over time, based on quarterly financial data.
Sk Biopharmaceuticals Co Ltd Competitors by Total Liabilities
The table below lists competitors of Sk Biopharmaceuticals Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Aurizon Holdings Ltd
AU:AZJ
|
Australia | AU$7.48 Billion |
|
Sotera Health Co
NASDAQ:SHC
|
USA | $2.64 Billion |
|
Spirit Aerosystems Holdings Inc
NYSE:SPR
|
USA | $10.62 Billion |
|
TFS Financial Corporation
NASDAQ:TFSL
|
USA | $16.12 Billion |
|
Amentum Holdings Inc.
NYSE:AMTM
|
USA | $6.41 Billion |
|
Shanghai Wanye Enterprises Co Ltd
SHG:600641
|
China | CN¥4.10 Billion |
|
Ningbo Orient Wires and Cables Co Ltd
SHG:603606
|
China | CN¥9.00 Billion |
|
Grupo Aeroportuario del Centro Norte SAB de CV
NASDAQ:OMAB
|
USA | $19.44 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down Sk Biopharmaceuticals Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Sk Biopharmaceuticals Co Ltd assets under control.
Liquidity & Leverage Metrics
Sk Biopharmaceuticals Co Ltd Total Liabilities Ratios Explained
Sk Biopharmaceuticals Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.49 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sk Biopharmaceuticals Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sk Biopharmaceuticals Co Ltd (2016–2025)
The table below shows the annual total liabilities of Sk Biopharmaceuticals Co Ltd from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩372.04 Billion ≈ $252.13 Million |
-19.62% |
| 2024-12-31 | ₩462.83 Billion ≈ $313.65 Million |
+15.07% |
| 2023-12-31 | ₩402.22 Billion ≈ $272.58 Million |
+15.69% |
| 2022-12-31 | ₩347.68 Billion ≈ $235.62 Million |
+74.31% |
| 2021-12-31 | ₩199.46 Billion ≈ $135.17 Million |
+64.61% |
| 2020-12-31 | ₩121.17 Billion ≈ $82.12 Million |
-20.33% |
| 2019-12-31 | ₩152.10 Billion ≈ $103.07 Million |
+312.12% |
| 2018-12-31 | ₩36.91 Billion ≈ $25.01 Million |
-27.81% |
| 2017-12-31 | ₩51.12 Billion ≈ $34.65 Million |
+10.64% |
| 2016-12-31 | ₩46.21 Billion ≈ $31.31 Million |
-- |
About Sk Biopharmaceuticals Co Ltd
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; Relenopride, wh… Read more